Sales of Biohaven's migraine tablet exceed expectations
Biohaven's tablet for preventive and acute treatment of episodic migraines has surpassed market expectations for the second quarter.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
After Biohaven's migraine drug Nurtec ODT was approved for preventative treatment of episodic migraines in addition to its previous approval as an acute treatment, sales have exploded.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves migraine pill as preventative treatment
For subscribers
